CN110038043A - 一种葛根排毒营养粉及其制备方法和应用 - Google Patents
一种葛根排毒营养粉及其制备方法和应用 Download PDFInfo
- Publication number
- CN110038043A CN110038043A CN201910241163.1A CN201910241163A CN110038043A CN 110038043 A CN110038043 A CN 110038043A CN 201910241163 A CN201910241163 A CN 201910241163A CN 110038043 A CN110038043 A CN 110038043A
- Authority
- CN
- China
- Prior art keywords
- pueraria lobata
- toxin expelling
- nutrient powder
- parts
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000010575 Pueraria lobata Nutrition 0.000 title claims abstract description 94
- 239000000843 powder Substances 0.000 title claims abstract description 71
- 239000003053 toxin Substances 0.000 title claims abstract description 55
- 231100000765 toxin Toxicity 0.000 title claims abstract description 55
- 235000015097 nutrients Nutrition 0.000 title claims abstract description 54
- 238000002360 preparation method Methods 0.000 title claims abstract description 50
- 241000219781 Pueraria montana var. lobata Species 0.000 title claims abstract 20
- 239000000284 extract Substances 0.000 claims abstract description 50
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 45
- 239000000654 additive Substances 0.000 claims abstract description 30
- 210000000582 semen Anatomy 0.000 claims abstract description 24
- 235000012907 honey Nutrition 0.000 claims abstract description 22
- 239000002994 raw material Substances 0.000 claims abstract description 14
- 241000208689 Eucommia ulmoides Species 0.000 claims abstract 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 64
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 54
- 235000019441 ethanol Nutrition 0.000 claims description 32
- 238000000034 method Methods 0.000 claims description 32
- 239000000463 material Substances 0.000 claims description 23
- 238000009777 vacuum freeze-drying Methods 0.000 claims description 23
- 239000006228 supernatant Substances 0.000 claims description 20
- 238000000605 extraction Methods 0.000 claims description 17
- 241001107116 Castanospermum australe Species 0.000 claims description 16
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 16
- 235000021279 black bean Nutrition 0.000 claims description 16
- 239000012153 distilled water Substances 0.000 claims description 16
- 239000000706 filtrate Substances 0.000 claims description 16
- 238000001914 filtration Methods 0.000 claims description 16
- 238000010992 reflux Methods 0.000 claims description 16
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims description 15
- 239000006187 pill Substances 0.000 claims description 12
- 238000002386 leaching Methods 0.000 claims description 11
- 230000001376 precipitating effect Effects 0.000 claims description 11
- 235000009508 confectionery Nutrition 0.000 claims description 10
- 239000012141 concentrate Substances 0.000 claims description 8
- 238000010438 heat treatment Methods 0.000 claims description 8
- 239000012535 impurity Substances 0.000 claims description 8
- 239000003208 petroleum Substances 0.000 claims description 8
- 238000010298 pulverizing process Methods 0.000 claims description 8
- 239000002775 capsule Substances 0.000 claims description 6
- 239000008187 granular material Substances 0.000 claims description 6
- 229940100688 oral solution Drugs 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 6
- 239000003826 tablet Substances 0.000 claims description 6
- 239000006286 aqueous extract Substances 0.000 claims description 5
- 238000000502 dialysis Methods 0.000 claims description 5
- 238000012869 ethanol precipitation Methods 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 238000001556 precipitation Methods 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 5
- 201000002282 venous insufficiency Diseases 0.000 claims description 5
- 239000000047 product Substances 0.000 claims description 2
- 238000005119 centrifugation Methods 0.000 claims 1
- 230000014759 maintenance of location Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 10
- 210000004185 liver Anatomy 0.000 abstract description 9
- 231100000753 hepatic injury Toxicity 0.000 abstract description 3
- 230000002195 synergetic effect Effects 0.000 abstract description 3
- 230000001154 acute effect Effects 0.000 abstract description 2
- 230000001225 therapeutic effect Effects 0.000 abstract description 2
- 244000046146 Pueraria lobata Species 0.000 description 74
- 244000237330 gutta percha tree Species 0.000 description 23
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 18
- 241000700159 Rattus Species 0.000 description 10
- 239000002552 dosage form Substances 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- SEBFKMXJBCUCAI-HKTJVKLFSA-N silibinin Chemical group C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-HKTJVKLFSA-N 0.000 description 9
- 238000011049 filling Methods 0.000 description 7
- 238000002156 mixing Methods 0.000 description 7
- 108010081577 aldehyde dehydrogenase (NAD(P)+) Proteins 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 208000010706 fatty liver disease Diseases 0.000 description 6
- 230000008859 change Effects 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000000470 constituent Substances 0.000 description 5
- 208000007082 Alcoholic Fatty Liver Diseases 0.000 description 4
- 206010016262 Fatty liver alcoholic Diseases 0.000 description 4
- 208000026594 alcoholic fatty liver disease Diseases 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000035622 drinking Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000013049 sediment Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 2
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 2
- 208000022309 Alcoholic Liver disease Diseases 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 208000004930 Fatty Liver Diseases 0.000 description 2
- 206010019708 Hepatic steatosis Diseases 0.000 description 2
- 206010019837 Hepatocellular injury Diseases 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 231100000437 hepatocellular injury Toxicity 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000011552 rat model Methods 0.000 description 2
- 231100000240 steatosis hepatitis Toxicity 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- 235000020097 white wine Nutrition 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 241000415078 Anemone hepatica Species 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 108010001202 Cytochrome P-450 CYP2E1 Proteins 0.000 description 1
- 102100024889 Cytochrome P450 2E1 Human genes 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- SEBFKMXJBCUCAI-UHFFFAOYSA-N NSC 227190 Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC=C(C=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 241000219780 Pueraria Species 0.000 description 1
- 240000006394 Sorghum bicolor Species 0.000 description 1
- 235000011684 Sorghum saccharatum Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000256856 Vespidae Species 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- IKHGUXGNUITLKF-XPULMUKRSA-N acetaldehyde Chemical compound [14CH]([14CH3])=O IKHGUXGNUITLKF-XPULMUKRSA-N 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 125000005909 ethyl alcohol group Chemical group 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- VUZPPFZMUPKLLV-UHFFFAOYSA-N methane;hydrate Chemical compound C.O VUZPPFZMUPKLLV-UHFFFAOYSA-N 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 229950000628 silibinin Drugs 0.000 description 1
- 235000014899 silybin Nutrition 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 235000014101 wine Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L11/00—Pulses, i.e. fruits of leguminous plants, for production of food; Products from legumes; Preparation or treatment thereof
- A23L11/05—Mashed or comminuted pulses or legumes; Products made therefrom
- A23L11/07—Soya beans, e.g. oil-extracted soya bean flakes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L21/00—Marmalades, jams, jellies or the like; Products from apiculture; Preparation or treatment thereof
- A23L21/20—Products from apiculture, e.g. royal jelly or pollen; Substitutes therefor
- A23L21/25—Honey; Honey substitutes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
- A61K35/644—Beeswax; Propolis; Royal jelly; Honey
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/46—Eucommiaceae (Eucommia family), e.g. hardy rubber tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Botany (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Polymers & Plastics (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Insects & Arthropods (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Agronomy & Crop Science (AREA)
- Animal Husbandry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及一种葛根排毒营养粉,由下述重量配比的原料制得:80%以上的葛根,20%以下的其他添加物,其中所述其他添加物包括黑豆40‑60份,蜂蜜20‑50份。本发明还涉及一种葛根排毒营养粉的制备方法和应用。实验证实,所述的葛根排毒营养粉在服用后能够对急性酒精性肝损伤具有显著的治疗效果,本发明所述的葛根排毒营养粉中三种组分在解酒减毒方面具有显著的协同作用,在此基础上使用杜仲提取物可以进一步增强其保肝疗效,其制备工艺简单,携带方便,可以进行推广应用。
Description
技术领域
本发明属于保健食品技术领域,具体涉及一种葛根排毒营养粉及其制备方法和应用。
背景技术
当乙醛含量过高时人体无法及时分解,乙醛进入血液并被吸收,导致对人体重要器官和功能严重损伤。解酒的关键在于如何使人体重要器官以及中枢神经、血液尽量少接触由酒精(乙醇)进入人体后产生的有毒物质“乙醛”,降低乙醛对细胞的氧化能力。酒精就是乙醇,人体内若是具备乙醇脱氢酶,就能使乙醇分解成乙醛。乙醛再经过乙醛脱氢酶的分解,变成乙酸。乙酸对人体没有危害,然后又会被分解成二氧化碳和水。乙醇和乙醛对人体危害最大。在人体中,都存在乙醇脱氢酶,而且数量基本是相等的。但缺少乙醛脱氢酶的人就比较多。这种乙醛脱氢酶的缺少,使乙醛不能被完全分解为乙酸,而是以乙醛继续留在体内,使人喝酒后产生恶心欲吐、昏迷不适等醉酒症状。因此,不善饮酒,酒量在合理标准以下的人,即属于乙醛脱氢酶数量不足或完全缺乏的人。对于善饮酒的人,如果饮酒过多、过快,超过了乙醛脱氢酶的分解能力,也会发生醉酒。
酒精性肝损伤的发病机制尚未完全阐明,中医认为肝血瘀阻为酒精性肝病的病理基础,故以疏肝清热、化痰利湿、活血祛瘀为主要治则。现代医学认为,酒精性肝病与酒精及其代谢产物乙醛的肝毒性、代谢障碍、氧化应激、炎症和细胞因子的释放、细胞凋亡等多种因素有关。血清ALT是诊断肝细胞损伤的灵敏指标,AST/ALT比值倒置,提示肝细胞损伤程度较重。MDA含量和GSH-Px活性可反映体内脂质过氧化反应程度。CYP2E1是肝细胞中参与氧化应激和脂质过氧化过程中的关键酶,对促进肝炎症和纤维化起重要作用,可导致抗氧化剂GSH、维生素E的含量显著下降,也能引起MDA、肿瘤坏死因子-α(TNF-α)生成增加,使自由基的生成增多,最终导致肝细胞结构与功能的损害。
发明内容
本发明提供一种葛根排毒营养粉及其制备方法和应用,其由葛根、黑豆和蜂蜜制备得到,其中葛根占80%以上,黑豆、蜂蜜等其他添加物占20%以下,实验证实,所述的葛根排毒营养粉在服用后可以显著提高乙醛脱氢酶的活性,并且能够对急性酒精性肝损伤具有显著的治疗效果。
本发明公开了一种葛根排毒营养粉,由下述重量配比的原料制得:80%以上的葛根,20%以下的其他添加物,其中所述其他添加物包括黑豆40-60 份,蜂蜜20-50份。
优选地,由下述重量配比的原料制得:85%的葛根,15%的其他添加物,其中所述其他添加物包括黑豆50份,蜂蜜35份。此时,本发明所述的葛根排毒营养粉的酶活促进效果和肝脏保护作用最强。
作为本发明所优选的一种实施方式,所述的其他添加物还包括杜仲提取物6-8份,更优选地,所述的其他添加物包括杜仲提取物7份。其中杜仲提取物的提取方法为:取新鲜杜仲真空冷冻干燥24-36h得干燥物,取干燥物按 1:60-80(m/V)料液比加入蒸馏水,70-90℃搅拌浸提2-4h,8000r/min离心 10min,得到上清液和沉淀,将上清液减压浓缩、真空冷冻干燥得水提物,取水提物用蒸馏水溶解,经终体积分数80%乙醇沉淀12-16h,8000r/min离心10min,得上清液和沉淀,上清液减压浓缩、真空冷冻干燥得到水提醇溶物,沉淀经真空冷冻干燥得水提醇沉物,取水提醇沉物用蒸馏水溶解,经 Sevage法脱蛋白、截留分子质量为3500D透析袋透析48h、真空冷冻干燥得水提粗多糖,将水体粗多糖和水提醇溶物混合均匀即得杜仲提取物。
本发明还提供一种上述葛根排毒营养粉的制备方法,其具体包括如下步骤:
1)取一定重量份葛根药材粉碎后过30-50目筛,加药材重量20-30倍体积的70%乙醇水溶液浸泡0.5-2.5小时,加热回流提取1-3小时,滤过得到一次滤液,向药渣中加入其重量8-10倍体积的70%乙醇水溶液继续回流提取 1-3小时,过滤,合并两次滤液,减压回收乙醇,浓缩至每毫升含生药1-1.2g,向浓缩液中加入与其等体积的石油醚进行萃取,同法萃取3次,去除脂溶性杂质,然后加入等体积的正丁醇进行萃取,同法萃取3次,合并正丁醇萃取相,将正丁醇萃取相真空干燥,即得葛根提取物;
2)将黑豆磨成粉后过60-80目筛得到黑豆粉;将葛根提取物、黑豆粉以及其他原料等按照重量份数比混合,然后按照常规制备工艺制备得到常用口服制剂。
所述的口服制剂为片剂、颗粒剂、胶囊剂、滴丸剂、丸剂或者口服液。其中所述的剂型均可采用本领域该剂型常规的制备方法和辅料进行,在不改变活性成分的前提下,剂型的改变不影响葛根排毒营养粉的临床效果。
作为本发明更优选的一种实施方式,所述的葛根排毒营养粉由下述重量配比的原料制得:85%的葛根,15%的其他添加物,其中所述其他添加物包括黑豆50份,蜂蜜35份、杜仲提取物7份。
根据申请人的临床效果探索,本发明还提供一种该葛根排毒营养粉的应用,即所述葛根排毒营养粉在制备治疗醒酒护肝产品中的应用。
本发明所述的葛根排毒营养粉中含有葛根,黑豆和蜂蜜等组分,三种组分在解酒减毒方面具有显著的协同作用,在此基础上使用杜仲提取物可以进一步增强其保肝疗效,其制备工艺简单,携带方便,可以进行推广应用。
具体实施方式
以下通过具体实施例进一步描述本发明,但所述实施例并不以任何方式限定本发明专利保护的范围。
实施例1本发明葛根排毒营养粉及其制备方法
一种葛根排毒营养粉,其由下述重量配比的原料制得:90%的葛根(540 份),10%的其他添加物,其中所述其他添加物包括黑豆40份,蜂蜜20份。
上述的葛根排毒营养粉的制备方法包括下述步骤:
1)取540份葛根药材粉碎后过30目筛,加药材重量20倍体积的70%乙醇水溶液浸泡0.5小时,加热回流提取1小时,滤过得到一次滤液,向药渣中加入其重量8倍体积的70%乙醇水溶液继续回流提取1小时,过滤,合并两次滤液,减压回收乙醇,浓缩至每毫升含生药1g,向浓缩液中加入与其等体积的石油醚进行萃取,同法萃取3次,去除脂溶性杂质,然后加入等体积的正丁醇进行萃取,同法萃取3次,合并正丁醇萃取相,将正丁醇萃取相真空干燥,即得葛根提取物;
2)将黑豆磨成粉后过60目筛得到黑豆粉;将葛根提取物、黑豆粉以及蜂蜜按照重量份数比混合,然后按照常规制备工艺制备得到常用口服制剂。
所述的口服制剂为片剂、颗粒剂、胶囊剂、滴丸剂、丸剂或者口服液。其中所述的剂型均可采用本领域该剂型常规的制备方法和辅料进行,在不改变活性成分的前提下,剂型的改变不影响葛根排毒营养粉的临床效果。
实施例2本发明葛根排毒营养粉及其制备方法
一种葛根排毒营养粉,其由下述重量配比的原料制得:81%的葛根(469 份),19%的其他添加物,其中所述其他添加物包括黑豆60份,蜂蜜50份。
所述的葛根排毒营养粉制备方法包括下述步骤:
1)取469份葛根药材粉碎后过50目筛,加药材重量30倍体积的70%乙醇水溶液浸泡2.5小时,加热回流提取3小时,滤过得到一次滤液,向药渣中加入其重量10倍体积的70%乙醇水溶液继续回流提取3小时,过滤,合并两次滤液,减压回收乙醇,浓缩至每毫升含生药1.2g,向浓缩液中加入与其等体积的石油醚进行萃取,同法萃取3次,去除脂溶性杂质,然后加入等体积的正丁醇进行萃取,同法萃取3次,合并正丁醇萃取相,将正丁醇萃取相真空干燥,即得葛根提取物;
2)将黑豆磨成粉后过80目筛得到黑豆粉;将葛根提取物、黑豆粉以及蜂蜜按照重量份数比混合,然后按照常规制备工艺制备得到常用口服制剂。
所述的口服制剂为片剂、颗粒剂、胶囊剂、滴丸剂、丸剂或者口服液。其中所述的剂型均可采用本领域该剂型常规的制备方法和辅料进行,在不改变活性成分的前提下,剂型的改变不影响葛根排毒营养粉的临床效果。
实施例3本发明葛根排毒营养粉及其制备方法
一种葛根排毒营养粉,其由下述重量配比的原料制得:85%的葛根(482 份),15%的其他添加物,其中所述其他添加物包括黑豆50份,蜂蜜35份。
所述的葛根排毒营养粉的制备方法包括下述步骤:
1)取485份葛根药材粉碎后过40目筛,加药材重量25倍体积的70%乙醇水溶液浸泡1.5小时,加热回流提取2小时,滤过得到一次滤液,向药渣中加入其重量9倍体积的70%乙醇水溶液继续回流提取1-3小时,过滤,合并两次滤液,减压回收乙醇,浓缩至每毫升含生药1.1g,向浓缩液中加入与其等体积的石油醚进行萃取,同法萃取3次,去除脂溶性杂质,然后加入等体积的正丁醇进行萃取,同法萃取3次,合并正丁醇萃取相,将正丁醇萃取相真空干燥,即得葛根提取物。
2)将黑豆磨成粉后过60目筛得到黑豆粉;将葛根提取物、黑豆粉以及蜂蜜按照重量份数比混合,然后按照常规制备工艺制备得到常用口服制剂。
所述的口服制剂为片剂、颗粒剂、胶囊剂、滴丸剂、丸剂或者口服液。其中所述的剂型均可采用本领域该剂型常规的制备方法和辅料进行,在不改变活性成分的前提下,剂型的改变不影响葛根排毒营养粉的临床效果。
实施例4本发明葛根排毒营养粉及其制备方法
一种葛根排毒营养粉,其由下述重量配比的原料制得:90%的葛根(594 份),10%的其他添加物,其中所述其他添加物包括黑豆40份,杜仲提取物 6份,蜂蜜20份。
所述杜仲提取物的提取方法为:取新鲜杜仲真空冷冻干燥24h得干燥物,取干燥物按1:60(m/V)料液比加入蒸馏水,70℃搅拌浸提2h,8000r/min 离心10min,得到上清液和沉淀,将上清液减压浓缩、真空冷冻干燥得水提物,取水提物用蒸馏水溶解,经终体积分数80%乙醇沉淀12h,8000r/min离心10min,得上清液和沉淀,上清液减压浓缩、真空冷冻干燥得到水提醇溶物,沉淀经真空冷冻干燥得水提醇沉物,取水提醇沉物用蒸馏水溶解,经Sevage法脱蛋白、截留分子质量为3500D透析袋透析48h、真空冷冻干燥得水提粗多糖,将水体粗多糖和水提醇溶物混合均匀即得杜仲提取物。
所述的葛根排毒营养粉的制备方法包括下述步骤:
1)取594份葛根药材粉碎后过30目筛,加药材重量20倍体积的70%乙醇水溶液浸泡0.5小时,加热回流提取1小时,滤过得到一次滤液,向药渣中加入其重量8倍体积的70%乙醇水溶液继续回流提取1小时,过滤,合并两次滤液,减压回收乙醇,浓缩至每毫升含生药1g,向浓缩液中加入与其等体积的石油醚进行萃取,同法萃取3次,去除脂溶性杂质,然后加入等体积的正丁醇进行萃取,同法萃取3次,合并正丁醇萃取相,将正丁醇萃取相真空干燥,即得葛根提取物;
2)将黑豆磨成粉后过60-80目筛得到黑豆粉;按照杜仲提取物的制备方法制备得到杜仲提取物;将葛根提取物、黑豆粉、杜仲提取物以及蜂蜜按照重量份数比混合,然后按照常规制备工艺制备得到常用口服制剂。
所述的口服制剂为片剂、颗粒剂、胶囊剂、滴丸剂、丸剂或者口服液。其中所述的剂型均可采用本领域该剂型常规的制备方法和辅料进行,在不改变活性成分的前提下,剂型的改变不影响葛根排毒营养粉的临床效果。
实施例5本发明葛根排毒营养粉及其制备方法
一种葛根排毒营养粉,其由下述重量配比的原料制得:81%的葛根(504 份),19%的其他添加物,其中所述其他添加物包括黑豆60份,杜仲提取物 8份,蜂蜜50份。
所述杜仲提取物的提取方法为:取新鲜杜仲真空冷冻干燥36h得干燥物,取干燥物按1:80(m/V)料液比加入蒸馏水,90℃搅拌浸提4h,8000r/min 离心10min,得到上清液和沉淀,将上清液减压浓缩、真空冷冻干燥得水提物,取水提物用蒸馏水溶解,经终体积分数80%乙醇沉淀16h,8000r/min离心10min,得上清液和沉淀,上清液减压浓缩、真空冷冻干燥得到水提醇溶物,沉淀经真空冷冻干燥得水提醇沉物,取水提醇沉物用蒸馏水溶解,经Sevage法脱蛋白、截留分子质量为3500D透析袋透析48h、真空冷冻干燥得水提粗多糖,将水体粗多糖和水提醇溶物混合均匀即得杜仲提取物。
所述的葛根排毒营养粉的制备方法包括下述步骤:
1)取504份葛根药材粉碎后过50目筛,加药材重量30倍体积的70%乙醇水溶液浸泡2.5小时,加热回流提取3小时,滤过得到一次滤液,向药渣中加入其重量10倍体积的70%乙醇水溶液继续回流提取3小时,过滤,合并两次滤液,减压回收乙醇,浓缩至每毫升含生药1.2g,向浓缩液中加入与其等体积的石油醚进行萃取,同法萃取3次,去除脂溶性杂质,然后加入等体积的正丁醇进行萃取,同法萃取3次,合并正丁醇萃取相,将正丁醇萃取相真空干燥,即得葛根提取物;
2)将黑豆磨成粉后过60-80目筛得到黑豆粉;按照杜仲提取物的制备方法制备得到杜仲提取物;将葛根提取物、黑豆粉、杜仲提取物以及蜂蜜按照重量份数比混合,然后按照常规制备工艺制备得到常用口服制剂。
实施例6本发明葛根排毒营养粉及其制备方法
一种葛根排毒营养粉,其由下述重量配比的原料制得:85%的葛根(522 份),15%的其他添加物,其中所述其他添加物包括黑豆50份,杜仲提取物 7份,蜂蜜35份。
所述杜仲提取物的提取方法为:取新鲜杜仲真空冷冻干燥30h得干燥物,取干燥物按1:70(m/V)料液比加入蒸馏水,80℃搅拌浸提3h,8000r/min 离心10min,得到上清液和沉淀,将上清液减压浓缩、真空冷冻干燥得水提物,取水提物用蒸馏水溶解,经终体积分数80%乙醇沉淀14h,8000r/min离心10min,得上清液和沉淀,上清液减压浓缩、真空冷冻干燥得到水提醇溶物,沉淀经真空冷冻干燥得水提醇沉物,取水提醇沉物用蒸馏水溶解,经Sevage法脱蛋白、截留分子质量为3500D透析袋透析48h、真空冷冻干燥得水提粗多糖,将水体粗多糖和水提醇溶物混合均匀即得杜仲提取物。
所述的葛根排毒营养粉的制备方法包括下述步骤:
1)取522份葛根药材粉碎后过40目筛,加药材重量25倍体积的70%乙醇水溶液浸泡1.5小时,加热回流提取2小时,滤过得到一次滤液,向药渣中加入其重量9倍体积的70%乙醇水溶液继续回流提取1-3小时,过滤,合并两次滤液,减压回收乙醇,浓缩至每毫升含生药1.1g,向浓缩液中加入与其等体积的石油醚进行萃取,同法萃取3次,去除脂溶性杂质,然后加入等体积的正丁醇进行萃取,同法萃取3次,合并正丁醇萃取相,将正丁醇萃取相真空干燥,即得葛根提取物。
2)将黑豆磨成粉后过60-80目筛得到黑豆粉;按照杜仲提取物的制备方法制备得到杜仲提取物;将葛根提取物、黑豆粉、杜仲提取物以及蜂蜜按照重量份数比混合,然后按照常规制备工艺制备得到常用口服制剂。
本发明葛根排毒营养粉对酒精性脂肪肝的治疗
1酒精性脂肪肝模型的制备
使用体重为125~155g的清洁级健康成年雄性SD大鼠,自由饮用55°二锅头白酒配制成不同浓度及含10%白糖的酒水饮料,其白酒度按照5%、 10%、15%、20%、25%、30%、35%、40%(V/V)逐渐递增,每个浓度持续 10天,40%时维持20周,总造模时间30周,构建酒精性脂肪肝病理动物模型。各组大鼠实验期间均予自由进食全价营养颗粒饲料。
2分组与给药
模型大鼠适应性饲养1周后,随机分成正常组、模型组以及给药组,具体分组情况见下表,每组10只,每天下午14:30时灌胃药物,服用方法为加开水搅拌为透明的膏状服用,剂量如下:
正常对照组:灌胃给予同体积的蒸馏水;
模型对照组:灌胃给予同体积的蒸馏水;
水飞蓟宾组:灌胃给予25mg/(kg.d)水飞蓟宾;
低剂量组:灌胃给予本发明实施例1所制备葛根排毒营养粉合剂,生药给药量0.1g/(kg.d);
中剂量组:灌胃给予本发明实施例1所制备葛根排毒营养粉合剂,生药给药量1g/(kg.d);
高剂量组:灌胃给予本发明实施例1所制备葛根排毒营养粉合剂,生药给药量10g/(kg.d);
3检测指标
末次给药后,戊巴比妥钠麻醉大鼠,解剖,腹主静脉取血测定生化指标,取肝脏进行称重。
3.1.肝功能
试验结果表明(详见表1),酒精性脂肪肝模型组大鼠血清ALT、AST 含量与正常组相比大幅度升高,各给药组的大鼠血清ALT、AST含量与模型组相比明显下降,尤其是,复方各剂量组与模型组相比具有极显著性差异,与水飞蓟宾组相比有极显著性差异,这说明本发明葛根排毒营养粉各中药在对大鼠脂肪肝的预防或治疗上取得了协同性的作用。
表1本发明葛根排毒营养粉对大鼠模型肝功能的影响
组别 | ALT(U/L) | AST(U/L) |
正常对照组 | 30.95±6.07 | 42.57±7.59 |
模型对照组 | 284.26±60.14 | 467.31±62.75 |
水飞蓟宾组 | 196.26±39.02<sup>*</sup> | 332.54±53.54<sup>*</sup> |
实施例3低剂量组 | 78.33±16.25<sup>**##▼▼</sup> | 94.56±9.25<sup>**##▼▼</sup> |
实施例3中剂量组 | 61.40±13.43<sup>**##▼▼</sup> | 81.20±7.15<sup>**##▼▼</sup> |
实施例3高剂量组 | 57.14±15.28<sup>**##▼▼</sup> | 76.27±5.19<sup>**##▼▼</sup> |
实施例6低剂量组 | 52.34±11.24<sup>**##▼▼</sup> | 54.57±6.17<sup>**##▼▼</sup> |
实施例6中剂量组 | 47.48±12.19<sup>**##▼▼</sup> | 51.24±8.27<sup>**##▼▼</sup> |
实施例6高剂量组 | 33.18±9.62<sup>**##▼▼</sup> | 46.26±4.62<sup>**##▼▼</sup> |
与模型组比较,*P<0.05;与模型组比较,**P<0.01;
与水飞蓟宾组比较,#P<0.05;与水飞蓟宾组比较,##P<0.01;
3.2肝指数
试验结果表明(详见表2),酒精性脂肪肝模型组大鼠肝指数与正常组相比有极显著性差异,各给药组的大鼠的肝指数与模型组相比有极显著性差异,尤其是,复方各剂量组与水飞蓟宾组相比有显著性差异或极显著性差异,这说明本发明葛根排毒营养粉各中药在大鼠脂肪肝模型上,在降低肝脏指数这个指标上取得了很好的协同作用。
表2本发明葛根排毒营养粉对大鼠脏器指数的影响
与正常组比较,¥P<0.05;与正常组比较,¥¥P<0.01;
与模型组比较,*P<0.05;与模型组比较,**P<0.01;
与水飞蓟宾组比较,#P<0.05;与水飞蓟宾组比较,##P<0.01。
Claims (8)
1.一种葛根排毒营养粉,其特征在于,由下述重量配比的原料制得:80%以上的葛根,20%以下的其他添加物,其中所述其他添加物包括黑豆40-60份,蜂蜜20-50份。
2.根据权利要求1所述的葛根排毒营养粉,其特征在于,由下述重量配比的原料制得:85%的葛根,15%的其他添加物,其中所述其他添加物包括黑豆50份,蜂蜜35份。
3.根据权利要求1所述的葛根排毒营养粉,其特征在于,所述的其他添加物还包括杜仲提取物6-8份。
4.根据权利要求3所述的葛根排毒营养粉,其特征在于,由下述重量配比的原料制得:85%的葛根,15%的其他添加物,其中所述其他添加物包括黑豆50份,蜂蜜35份、杜仲提取物7份。
5.根据权利要求3或4所述的葛根排毒营养粉,其特征在于,所述的杜仲提取物的提取方法为:取新鲜杜仲真空冷冻干燥24-36h得干燥物,取干燥物按1:60-80料液比加入蒸馏水,70-90℃搅拌浸提2-4h,8000r/min离心10min,得到上清液和沉淀,将上清液减压浓缩、真空冷冻干燥得水提物,取水提物用蒸馏水溶解,经终体积分数80%乙醇沉淀12-16h,8000r/min离心10min,得上清液和沉淀,上清液减压浓缩、真空冷冻干燥得到水提醇溶物,沉淀经真空冷冻干燥得水提醇沉物,取水提醇沉物用蒸馏水溶解,经Sevage法脱蛋白、截留分子质量为3500D透析袋透析48h、真空冷冻干燥得水提粗多糖,将水体粗多糖和水提醇溶物混合均匀即得杜仲提取物。
6.一种如权利要求1-4任意一项所述的葛根排毒营养粉的制备方法,其特征在于包括如下步骤:
1)取一定重量份葛根药材粉碎后过30-50目筛,加药材重量20-30倍体积的70%乙醇水溶液浸泡0.5-2.5小时,加热回流提取1-3小时,滤过得到一次滤液,向药渣中加入其重量8-10倍体积的70%乙醇水溶液继续回流提取1-3小时,过滤,合并两次滤液,减压回收乙醇,浓缩至每毫升含生药1-1.2g,向浓缩液中加入与其等体积的石油醚进行萃取,同法萃取3次,去除脂溶性杂质,然后加入等体积的正丁醇进行萃取,同法萃取3次,合并正丁醇萃取相,将正丁醇萃取相真空干燥后粉碎,即得葛根提取物;
2)将黑豆磨成粉后过60-80目筛得到黑豆粉;将葛根提取物、黑豆粉以及其他原料等按照重量份数比混合,然后按照常规制备工艺制备得到常用口服制剂。
7.根据权利要求6所述的葛根排毒营养粉的制备方法,其特征在于,所述的口服制剂为片剂、颗粒剂、胶囊剂、滴丸剂、丸剂或者口服液。
8.根据权利要求1-4任意一项所述的葛根排毒营养粉在制备治疗醒酒护肝产品中的应用。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810270647 | 2018-03-29 | ||
CN2018102706474 | 2018-03-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN110038043A true CN110038043A (zh) | 2019-07-23 |
Family
ID=67275431
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910241163.1A Pending CN110038043A (zh) | 2018-03-29 | 2019-03-28 | 一种葛根排毒营养粉及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110038043A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116474070A (zh) * | 2023-04-23 | 2023-07-25 | 江苏恰瑞生物科技有限公司 | 一种治疗急性酒精性肝损伤的血液灌流填料的制备方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103860628A (zh) * | 2012-12-14 | 2014-06-18 | 湖北老龙洞杜仲开发有限公司 | 一种解酒醒酒中成药制剂及其制备方法 |
-
2019
- 2019-03-28 CN CN201910241163.1A patent/CN110038043A/zh active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103860628A (zh) * | 2012-12-14 | 2014-06-18 | 湖北老龙洞杜仲开发有限公司 | 一种解酒醒酒中成药制剂及其制备方法 |
Non-Patent Citations (2)
Title |
---|
季昌群等主编: "《解酒护肝宜吃的食物》", 28 February 2012, 金盾出版社 * |
李梅等主编: "《常见肝病营养与保健》", 30 June 2015, 人民军医出版社 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116474070A (zh) * | 2023-04-23 | 2023-07-25 | 江苏恰瑞生物科技有限公司 | 一种治疗急性酒精性肝损伤的血液灌流填料的制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107156573A (zh) | 一种解酒饮料及其制备方法 | |
CN101411761B (zh) | 苹果属花楸苹果组植物的新用途 | |
CN102150842A (zh) | 一种护肝解酒口服液及其制备方法 | |
CN102697047B (zh) | 一种枸杞口服液的制备方法 | |
CN104351610B (zh) | 一种抑制酒精吸收、促进酒精代谢的保健口服液及制备方法 | |
CN107951935A (zh) | 一种葛根枳椇子破壁组合物及其制备方法和应用 | |
US20180369308A1 (en) | Chinese herbal medicine composition having a function of relieving hypothyroidism, preparation method and use thereof | |
CN102894152B (zh) | 一种保健茶及其制备方法 | |
CN110038043A (zh) | 一种葛根排毒营养粉及其制备方法和应用 | |
CN104225295B (zh) | 用于改善睡眠的组合物及其制备方法和应用 | |
CN100464755C (zh) | 具有免疫调节作用的抗化学性肝损伤的中药制剂 | |
CN101953887A (zh) | 用于防治糖尿病并发症的药物组合物及其制备方法 | |
CN101559166B (zh) | 一种麦冬提取物及其制备方法与降糖应用 | |
CN104998085B (zh) | 一种可增强免疫功能的中药复方组合物及其制备方法 | |
CN100455300C (zh) | 野生猕猴桃复方吞咽片及其制备方法 | |
CN106421741A (zh) | 水溶性橄榄叶提取物保健品及其制备方法 | |
CN107158084B (zh) | 治疗桥本氏甲状腺炎的药物组合物及其制备方法和用途 | |
CN112716990A (zh) | 一种葵花盘提取物、含有葵花盘提取物的药物及制备方法和应用 | |
CN104783156B (zh) | 一种具有美容功能的黑醋酵素的制备方法 | |
CN110420258A (zh) | 一种具有壮阳功效的金樱根提取物及其制备方法和用途 | |
CN108686126A (zh) | 一种护肝解酒组方及制备与应用 | |
CN106474380A (zh) | 具有护肝解酒功效的中药组合物、制剂及其制备方法 | |
CN103907810A (zh) | 一种五红素制剂及其制备方法 | |
CN112641809B (zh) | 一种林蛙籽及其提取物在制备减肥药品和食品中的应用 | |
CN106619972A (zh) | 蝙蝠蛾被毛孢菌丝体粉降血糖胶囊、其制备方法及用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190723 |
|
RJ01 | Rejection of invention patent application after publication |